Lead Product(s): Adrecizumab
Therapeutic Area: Infections and Infectious Diseases
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2020
The study achieved its primary endpoint: Adrecizumab demonstrated a favorable safety profile and was well tolerated.